Simple £36 Cholesterol Test Could Better Predict Heart Attack Risk Than Standard Methods
A straightforward cholesterol test costing as little as £36 could be the crucial key to identifying individuals at heightened risk of suffering heart attacks and strokes, according to a significant new medical study. More than half of all British adults currently live with high cholesterol, a condition characterised by the accumulation of fatty substances in the blood that can lead to clogged arteries and severe cardiovascular complications.
The Limitations of Standard Cholesterol Testing
Cholesterol is typically assessed within the NHS by measuring levels of low-density lipoprotein (LDL-C), commonly referred to as 'bad' cholesterol. However, this standard approach does not directly measure the actual number of harmful, artery-damaging particles found within cholesterol, known as apolipoprotein B (apoB). Researchers from Northwestern Medicine in the United States have now discovered that measuring apoB levels could potentially save significantly more lives than the traditional testing methods which simply measure overall cholesterol levels.
The Superior Predictive Power of ApoB Testing
The apoB test, which is not routinely utilised within the National Health Service, specifically measures the precise number of these harmful particles present in a patient's bloodstream. This allows medical professionals to prescribe either preventative medication or recommend lifestyle modifications years before a patient actually falls seriously ill. To rigorously examine whether the apoB test was genuinely worthwhile, researchers employed a sophisticated simulation model involving 250,000 US adults who were eligible for statins—drugs designed to lower bad cholesterol—but who did not yet exhibit any overt cardiovascular disease.
Using this extensive dataset, the research team forecasted potential outcomes for the cohort if doctors prescribed medication based on three different blood test criteria: testing for 'bad' LDL cholesterol, testing for non-HDL cholesterol (which encompasses all cholesterol forms, including LDL), or testing specifically for levels of apoB. The findings were striking. The study concluded that focusing treatment decisions on apoB markers could prevent approximately 1,000 more heart attacks and strokes per 250,000 people than the current alternative clinical approaches.
Cost-Effectiveness and Improved Patient Outcomes
This preventative strategy could prove highly cost-effective for healthcare providers like the NHS, as it would help avoid the expensive emergency care and long-term recovery needs typically associated with treating heart attack and stroke patients. The study, which has been published in the prestigious journal JAMA, strongly suggests that wider adoption of apoB testing could substantially improve treatment decisions and patient outcomes across the board.
Ciaran Kohli-Lynch, the study's lead author and an assistant professor of preventive medicine at Northwestern University, stated: 'We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice.'
Expert Calls for NHS Adoption
Medical experts have previously called for the NHS to adopt this test—available for just £36 at many private high-street health clinics—more widely. However, one prominent cholesterol expert emphasised that it need not be an all-or-nothing approach. Dr Richard Webb from Liverpool Hope University has previously advocated for the NHS to use the apoB test in conjunction with current practices.
Dr Webb highlighted a critical gap in current testing: some patients may receive normal LDL cholesterol results that do not raise immediate concern, despite still being at significant risk due to other factors. 'Our findings show they could very well be consuming a poor diet and also be predisposed to chronic disease,' Dr Webb explained. While the number of patients missed by standard tests might be 'a relatively low number,' he added that it could still amount to many thousands of people across the UK who are not adequately warned about their latent risk of a heart attack or stroke.
The research underscores a growing consensus that integrating more precise biomarkers like apoB into routine cardiovascular screening could be a transformative step in preventative healthcare, offering a more accurate early warning system and potentially saving thousands of lives annually through timely intervention.
